Literature DB >> 25515508

Bacterial β-ketoacyl-acyl carrier protein synthase III (FabH) as a target for novel antibacterial agents design.

X Y Lu, J Tang, Z Zhang, K Ding1.   

Abstract

In bacterial type II fatty acid biosynthesis (FAS-II), β-ketoacyl-acyl carrier protein (ACP) synthase III (FabH) initiates the first condensation of acyl-CoA and malonyl-ACP to form acetoacetyl-ACP. Its key role for organism survival and specificity to bacteria make it as an essential target for the discovery of novel antibacterial agents. Over the last decade, several structures of FabH from diverse microorganisms have been solved, giving detailed information about the three-dimensional features of the catalytic pocket. This has facilitated the rational design of FabH inhibitors, which provides a framework for future development of antibiotics against multi-drug resistant strains. This review covers recent advances in the biochemical and structural research of FabH and updates the main families of related inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25515508     DOI: 10.2174/0929867322666141212115236

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  3 in total

1.  Differences in substrate specificity of V. cholerae FabH enzymes suggest new approaches for the development of novel antibiotics and biofuels.

Authors:  Jing Hou; Heping Zheng; Wen-Shyong Tzou; David R Cooper; Maksymilian Chruszcz; Mahendra D Chordia; Keehwan Kwon; Marek Grabowski; Wladek Minor
Journal:  FEBS J       Date:  2018-06-30       Impact factor: 5.542

2.  A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China.

Authors:  Yan Zhou; Zishao Zhong; Shengjuan Hu; Jing Wang; Yanhong Deng; Ximei Li; Xianmei Chen; Xue Li; Yuanyuan Tang; Xiaofei Li; Qian Hao; Jun Liu; Tian Sang; Yang Bo; Feihu Bai
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

3.  Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with a 4-phenylthiazol-2-amine scaffold.

Authors:  Jan Zitko; Ondřej Jand'ourek; Pavla Paterová; Lucie Navrátilová; Jiří Kuneš; Jarmila Vinšová; Martin Doležal
Journal:  Medchemcomm       Date:  2018-02-22       Impact factor: 3.597

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.